THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENTCredit Agreement • February 23rd, 2015 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances) • New York
THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), dated as of November 4, 2014, is entered into by and among WELLSTAT DIAGNOSTICS, LLC, a limited liability company (the “Borrower”), PDL BIOPHARMA, INC., a Delaware corporation (the “Lender”), and PDL BIOPHARMA, INC., a Delaware corporation (the “Agent”).
EXCHANGE AGREEMENT (Unrestricted Stock)Exchange Agreement • February 23rd, 2015 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances)
Tang Capital Partners, LP (the “Holder”), for itself, enters into this Exchange Agreement (this “Agreement”) with PDL BioPharma, Inc., a Delaware corporation (the “Company”), on October 20, 2014, whereby the Holder will exchange the Company’s 2.875% Series 2012 Convertible Senior Notes due February 15, 2015 (the “Notes”) for shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), and a cash payment. The Notes were initially issued pursuant to that certain Indenture, dated as of January 5, 2012, between the Company and the Bank of New York Mellon Trust Company, N.A., as trustee (the “Indenture”). Capitalized terms not otherwise defined herein shall have the respective meanings ascribed to them in the Indenture.
SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENTCredit Agreement • February 23rd, 2015 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances) • New York
SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Second Amendment”), dated as of August 21, 2014, is entered into by and among WELLSTAT DIAGNOSTICS, LLC, a Delaware limited liability company (the “Borrower”), and PDL BIOPHARMA, INC., a Delaware corporation (“PDL”), in its capacity as lender (in such capacity, the “Lender”), and in its capacity as agent (in such capacity, the “Agent”).
